Clearance of HCV by Combination Therapy of Pegylated Interferon α-2a and Ribavirin Improves Insulin Resistance
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Chronic hepatitis C virus (HCV) infection is associated with a higher risk of the development of insulin resistance. If HCV is a causal factor for insulin resistance, then clearance of HCV might decrease insulin resistance. The aim of this study was to elucidate the effects of clearance of HCV on insulin resistance. Methods: We analyzed 28 patients with HCV infection who received combination treatment of 180 μg of pegylated interferon α-2a and ribavirin at our institution from May 2004 to November 2006. Insulin resistance was calculated according to the homeostasis model assessment of insulin resistance (HOMA-IR) method. Results: Twenty-two patients (78.6%) achieved sustained virologic response (SVR), where the fasting plasma glucose level significantly decreased after antiviral treatment. Fasting serum insulin and HOMA-IR also significantly decreased after antiviral treatment, whereas the BMI value was not significantly affected. For the nonresponders (n=6), no significant changes were evident in BMI, fasting plasma glucose, fasting serum insulin, and HOMA-IR at 6 months after the end of antiviral treatment. Logistic regression analysis indicated that the only independent factor contributing to the reduction of insulin resistance was the complete disappearance of HCV RNA at 6 months after the end of antiviral treatment (SVR). Conclusions: The clearance of HCV by the combination therapy of pegylated interferon α-2a and ribavirin improves insulin resistance by reducing fasting serum insulin and glucose levels.
Abstract
Background/Aims: Chronic hepatitis C virus (HCV) infection is associated with a higher risk of the development of insulin resistance. If HCV is a causal factor for insulin resistance, then clearance of HCV might decrease insulin resistance. The aim of this study was to elucidate the effects of clearance of HCV on insulin resistance. Methods: We analyzed 28 patients with HCV infection who received combination treatment of 180 μg of pegylated interferon α-2a and ribavirin at our institution from May 2004 to November 2006. Insulin resistance was calculated according to the homeostasis model assessment of insulin resistance (HOMA-IR) method. Results: Twenty-two patients (78.6%) achieved sustained virologic response (SVR), where the fasting plasma glucose level significantly decreased after antiviral treatment. Fasting serum insulin and HOMA-IR also significantly decreased after antiviral treatment, whereas the BMI value was not significantly affected. For the nonresponders (n=6), no significant changes were evident in BMI, fasting plasma glucose, fasting serum insulin, and HOMA-IR at 6 months after the end of antiviral treatment. Logistic regression analysis indicated that the only independent factor contributing to the reduction of insulin resistance was the complete disappearance of HCV RNA at 6 months after the end of antiviral treatment (SVR). Conclusions: The clearance of HCV by the combination therapy of pegylated interferon α-2a and ribavirin improves insulin resistance by reducing fasting serum insulin and glucose levels.
참고문헌 (24)
- Allison ME, "Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population", J Hepatol, 21, pp.1135~1139 (1994)
- Mason AL, "Association of diabetes mellitus and chronic hepatitis C virus infection", Hepatology, 29, pp.328~333 (1999)
- Hui JM, "Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression", Gastroenterology, 125, pp.1695~1704 (2003)
- Adami HO, "Excess risk of primary liver cancer in patients with diabetes mellitus", J Natl Cancer Inst, 88, pp.1472~1477 (1996)
- El-Serag HB, "Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma", Gastroenterology, 126, pp.460~468 (2004)
- Nagao Y, "Extrahepatic manifestations and insulin resistance in an HCV hyperendemic area", Int J Mol Med, 16, pp.291~296 (2005)
- Sumie S, "Significance of glucose intolerance and SHIP2 expression in hepatocellular carcinoma patients with HCV infection", Oncol Rep, 18, pp.545~552 (2007)
- Harrison SA, "Correlation between insulin resistance and hepatitis C viral load", Hepatology, 43, pp.1168~ (2006)
- Sanyal AJ, "Hyperinsulinemia blocks the inhibition of hepatitis C virus (HCV) replication by interferon: a potential mechanism for failure of interferon therapy in subjects with HCV and nonalcoholic fatty liver disease", Hepatology, 40, pp.179A~ (2004)
- Romero-Gómez M, "Insulin resistance impairs sustained response rate to pe ginterferon plus ribavirin in chronic hepatitis C patients", Gastroenterology, 128, pp.636~641 (2005)
- Konrad T, "Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon- alpha", Eur J Clin Invest, 30, pp.111~121 (2000)
- Kawaguchi T, "Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2", Am J Gastroenterol, 102, pp.570~576 (2007)
- Simmonds P, "Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region", J Gen Virol, 74, pp.2391~2399 (1993)
- Chiles R, "Excessive serum insulin response to oral glucose in obesity and mild diabetes. Study of 501 patients", Diabetes, 19, pp.458~464 (1970)
- Bahtiyar G, "Association of diabetes and hepatitis C infection: epidemiologic evidence and pathophysiologic insights", Curr Diab Rep, 4, pp.194~198 (2004)
- Shintani Y, "Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance", Gastroenterology, 126, pp.840~848 (2004)
- Kawaguchi T, "Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3", Am J Pathol, 165, pp.1499~1508 (2004)
- Kawaguchi T, "Causal relationship between hepatitis C virus core and the development of type 2 diabetes mellitus in a hepatitis C virus hyperendemic area: a pilot study", Int J Mol Med, 16, pp.109~114 (2005)
- Koivisto VA, "Effect of interferon on glucose tolerance and insulin sensitivity", Diabetes, 38, pp.641~647 (1989)
- Imano E, "Interferon induces insulin resistance in patients with chronic active hepatitis C", J Hepatol, 28, pp.189~193 (1998)
- Ito Y, "Effects of long-term interferon-alpha treatment on glucose tolerance in patients with chronic hepatitis C", J Hepatol, 31, pp.215~220 (1999)
- Tai TY, "Interferon-alpha reduces insulin resistance and beta-cell secretion in responders among patients with chronic hepatitis B and C", J Endocrinol, 178, pp.457~465 (2003)
- Moucari R, "Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis", Gastroenterology, 134, pp.416~423 (2008)
- Hui JM, "Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression", Gastroenterology, 125, pp.1695~1704 (2003)